Ray Dalio's ADMA Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 60.3K shares of ADMA Biologics, Inc. (ADMA) worth $883,734, representing 0.00% of the portfolio. First purchased in 2025-Q3, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Ray Dalio has initiated a new position in ADMA, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's ADMA Biologics (ADMA) Holding Value Over Time
Track share changes against reported price movement
Quarterly ADMA Biologics (ADMA) Trades by Ray Dalio
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2025 | +60,282 | New Buy | 60,282 | $14.66 |
Ray Dalio's ADMA Biologics Investment FAQs
Ray Dalio first purchased ADMA Biologics, Inc. (ADMA) in Q3 2025, acquiring 60,282 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held ADMA Biologics, Inc. (ADMA) for 1 quarters since Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's largest addition to ADMA Biologics, Inc. (ADMA) was in Q3 2025, adding 60,282 shares worth $883,734. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 60,282 shares of ADMA Biologics, Inc. (ADMA), valued at approximately $883,734. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, ADMA Biologics, Inc. (ADMA) represents approximately 0.00% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's peak holding in ADMA Biologics, Inc. (ADMA) was 60,282 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.